Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Aurinia Pharmaceuticals Inc. (AUPH) stock rallied over 3.50% intraday to trade at $11.54 a share on NASDAQ. The stock opened with a gain of 9.07% at $11.21 and touched an intraday high of $11.8, rising 3.50% against the last close of $11.15. The stock went to a low of $11.17 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $11.21 | $11.8 | $11.17 | $11.54 | 2,217,500 |
2022-06-22 | $10.58 | $11.54 | $10.58 | $11.15 | 2,177,200 |
2022-06-21 | $10.82 | $11.51 | $10.75 | $10.79 | 2,482,000 |
2022-06-17 | $9.94 | $11.27 | $9.94 | $10.63 | 3,446,000 |
2022-06-16 | $9.67 | $9.955 | $9.395 | $9.91 | 2,372,500 |
2022-06-15 | $9.41 | $10.095 | $9.32 | $9.91 | 2,878,700 |
2022-06-14 | $10.23 | $10.305 | $9.18 | $9.45 | 3,593,000 |
2022-06-13 | $11.24 | $11.36 | $9.6 | $10.14 | 4,020,700 |
2022-06-10 | $11.87 | $12.07 | $11.55 | $11.69 | 1,675,700 |
2022-06-09 | $12.72 | $12.72 | $11.585 | $12.09 | 2,693,400 |
Employees-
Beta1.1
Sales or Revenue45.6 Million
5Y Sales Change204.90%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock price is $11.54 as of the last check on Thursday, June 23. During the trading session, AUPH stock reached the peak price of $11.8 while $11.17 was the lowest point it dropped to.
The NASDAQ listed AUPH is part of Biotechnology industry that operates in the broader Health Care sector. Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
Dr. Glenn Schulman
Sr. VP of Corp. Communications & Investor Relations
Mr. Peter S. Greenleaf M.B.A.
Pres, CEO & Director
Mr. Joseph M. Miller CPA
Chief Financial Officer
Mr. Matthew Maxwell Donley M.B.A.
Exec. VP of Operations & Strategy
AUPH stock traded closed the last session at $11.54, which is $0.39 or 3.50% lower than its previous close of $11.15. AUPH's current trading price is 30.25% lower than its 52-week high of $33.97 where as its distance from 52-week low of 8.86% is -66.03%.
Number of AUPH employees currently stands at -. AUPH operates from 4464 Markham Street, Suite 1203, Victoria, BC V8Z 7X8, Canada.
Official Webiste of $AUPH is: https://www.auriniapharma.com
AUPH could be contacted at AUPH operates from 4464 Markham Street, Suite 1203, Victoria, BC V8Z 7X8, Canada, or at phone # and can also be accessed through its website.
AUPH stock volume for the day was 2,214,714 shares while in the previous session number of AUPH shares traded was 2,217,500 . The average number of AUPH shares traded daily for last 3 months was 2.06 Million.
The percentage change in AUPH stock occurred in the recent session was 3.50% while the dollar amount for the price change in AUPH stock was $0.39.
In the recent session, the day high for AUPH stock was $11.8 while the low for AUPH stock touched on the day was $11.17.
The market value of AUPH currently stands at 1.52 Billion with its latest stock price at $11.54 and 141.68 Million of its shares outstanding.